|Bid||42.10 x 100|
|Ask||45.74 x 300|
|Day's range||44.20 - 46.98|
|52-week range||11.41 - 46.98|
|PE ratio (TTM)||N/A|
|Earnings date||1 Nov 2017 - 6 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.50|
Stocks that moved substantially or traded heavily Monday: General Electric Co., down $1.47 to $19.02 The industrial company cut its dividend in half and gave a disappointing profit forecast for 2018. GGP ...
Nektar launched to a nearly 17-year high Monday on strong combination data for its immuno-oncology drug combined with Bristol-Myers Squibb's Opdivo in skin, kidney and lung cancers.
Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.
Shares of Nektar Therapeutics soared 26% in premarket trade Monday, putting them on track to open at the highest level seen since January 2001, after the biopharmaceutical company announced over the weekend ...
On a per-share basis, the San Francisco-based company said it had net income of 37 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Tesaro, Acadia and Nektar topped third-quarter sales expectations. Nektar turned around year-earlier losses, while Acadia and Tesaro reported better-than-expected losses.
Nektar rocketed to a 16-year high Tuesday after an analyst initiated coverage of it with an outperform rating.